. 2016 Jul 4;23:52. doi: 10.1186/s12929-016-0268-x

Table 2.

Intervention studies reporting plasma or serum peroxidation biomarkers and Total Antioxidant Capacity in psoriasis: association with inflammation and lipid profile

Ref.	N° subjects: Treatment	Peroxidation	TAC	Inflammation	Lipid profile
Ref.	Duration (study design)	Peroxidation	TAC	Inflammation	Lipid profile
[33]	7: topical treatment^a		↑
[33]	Single application		↑
[28]	67: topical treatment^b	↓ TBARS
[28]	20 days	↓ TBARS
[57]	67: topical treatment^b	↓ TBARS
[57]	20 days	↓ TBARS
[26]	10: topical treatment^c	↓ TBARS	↔	↔ CRP	↔ CHOL, LDL, HDL, TG
	10: topical treatment^c	↔ oxLDL	↔	↔ CRP	↔ CHOL, LDL, HDL, TG
	11: NB UVB	↔ TBARS, oxLDL	↔	↓ CRP	↔ CHOL, LDL, HDL, TG
	13: PUVA	↔ TBARS, oxLDL	↓	↓ CRP	↔ CHOL, LDL, HDL, TG
	3, 6, and 12 weeks (3 treatments in parallel)	↔ TBARS, oxLDL	↓	↓ CRP	↔ CHOL, LDL, HDL, TG
[27]	10: topical treatment^c	↓ TBARS	↔	↔ CRP
	17: NB UVB	↓ TBARS	↔	↓ CRP
	20: PUVA	↓ TBARS	↔	↓ CRP
	3, 6, and 12 weeks (2 treatments in parallel)	↓ TBARS	↔	↓ CRP
[39]	32: BB UVB	↑ TBARS
[39]	21 weeks (longitudinal)	↑ TBARS
[59]	24: NB UVB	↑ TOS	↔	↔ CRP
[59]	30 sessions (longitudinal)	↑ TOS	↔	↔ CRP
[60]	3: MMF	↔ MDA		↔ CRP
[60]	1 months (longitudinal)	↔ MDA		↔ CRP
[29]	58: MTX	↑ MDA	↔
[29]	6 and 12 weeks (longitudinal)	↑ MDA	↔
[61]	26: MTX	↔ TOS	↔		↓ CHOL, LDL, HDL
[61]	8 weeks (longitudinal)	↔ TOS	↔		↓ CHOL, LDL, HDL
[21]	13: Infliximab	↓ MDA	↔	↓ ROS
[21]	6 months (parallel: treated versus 16 untreated patients)	↓ MDA	↔	↓ ROS
[62]	23: Etanercept	↓ peroxides	↑	↓ CRP	↔ CHOL, LDL, HDL, TG
[62]	24 weeks (longitudinal)	↓ peroxides	↑	↓ CRP	↔ CHOL, LDL, HDL, TG
[44]	24: Efalizumab	↓ MDA		↔ IL-8
[44]	12-week (longitudinal)	↓ MDA		↓ Ex-vivo TNF-α and IFN-γ

BB UVB: broad-band UVB; CHOL: cholesterol; CRP: C-reactive protein; HDL: high-density lipoprotein; IFN: interferon; IL: interleukin; LDL: low-density lipoprotein; MDA: malondialdehyde; MMF: mycophenolate mofetil; MTX: Methotrexate; NB UVB: narrow-band UVB; oxLDL: oxidized low-density lipoprotein; PUVA: photochemotherapy; ROS: reactive oxygen species; TAC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substance; TG: triglycerides; TNF: tumor necrosis factor; TOS: total oxidant status; Topical treatment: ^afluocinolone acetonide, ^bsalicyl ointment, cignoline, tar, followed by bethametasone dipropionide with salicyl acid, ^ccalcipotriene (calcipotriol) or betamethasone dipropionate, or a combination of the two; ↑: increased; ↓: decreased; ↔: unchanged